FHTX vs FRT · rev $19.3M vs rev $1.28B
Foghorn Therapeutics Inc (FHTX) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Foghorn Therapeutics Inc (FHTX) is a biotechnology company listed on NASDAQ.
FRT (FRT) common stock.
Latest reported FHTX revenue for 2026-06-30 was $19.3M. Net income was -$27.1M. FHTX currently screens at market cap $237.8M.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
FHTX currently screens at market cap $237.8M. FRT currently screens at market cap $0.
Not investment advice. Open the FHTX and FRT stock pages for the full models.
Not investment advice.